Table 3.

(a–b) Univariate and multivariate analysis of prognostic factors of overall survival at the time of secondary cytotoxic chemotherapy for high-grade serous ovarian cancer recurrence in both the exploratory (3a) and validation (3b) cohorts. Endpoint was patient death irrespective of documented cause.

3a. Parameters Exploratory Cohort	Prognostic Value for Second-Line Chemotherapy
	Univariate Analysis		Multivariable Analysis
	p-Value	HR (95% CI)	p-Value
Log growth rate constant > −3.32	0.006	2.13 (1.37–3.32)	0.005	1.92 (1.22–3.03)
Therapy-free interval > 6 months	0.014	1.93 (0.96–3.87)	0.524	1.29 (0.59–2.82)
Age at time of therapy > 60 years	0.005	1.82 (1.17–2.85)	-	-
Platinum-based therapy yes/no	<0.001	2.66 (1.69–4.17)	0.001	2.34 (1.41–3.87)
Bevacizumab received yes/no	0.934	1.02 (0.60–1.76)	0.504	1.25 (0.65–2.38)
No primary surgery residual tumor (R0)	0.045	1.46 (0.93–2.29)	-	-
FIGO stage (2014) > FIGO IIIc	0.595	1.32 (0.66–2.65)	-	-
3b. Parameters Validation Cohort	Prognostic Value for Second-Line Chemotherapy
	Univariate Analysis		Multivariable Analysis
	p-Value	HR (95% CI)	p-Value
Log growth rate constant >−3.32	<0.001	3.31 (1.74–6.29)	0.002	2.90 (1.50–5.59)
Therapy-free interval >6 months	<0.001	1.44 (0.73–2.81)	0.642	1.13 (0.83–1.79)
Age at time of therapy >60 years	<0.001	1.58 (1.01–2.48)	-	-
Platinum-based therapy yes/no	0.001	2.10 (1.30–3.39)	0.015	2.23 (1.17–4.23)

CI: Confidence interval, FIGO: International Federation of Gynecology and Obstetrics, HR: Hazard ratio.